| 253 | 2 | 47 |
| 下载次数 | 被引频次 | 阅读次数 |
对引起手足口病的肠道病毒A组4型进行生物化学特性及免疫原性的研究。利用大肠杆菌表达结构蛋白全长或部分片段的GST融合蛋白，纯化CV-A4病毒颗粒，制备兔抗CV-A4 VP1～VP4蛋白及抗CV-A4病毒颗粒抗血清。以免疫印迹法（Western blotting,WB），结合SDS-PAGE电泳法，对CsCl密度梯度纯化的CV-A4的空心颗粒（EP）与实心颗粒（FP）的蛋白组分、纯度、多聚蛋白酶剪切进行分析。以微量中和法测定以上6种抗原免疫的兔或小鼠血清中和抗体效价，评估免疫原性。WB和间接免疫荧光法证明了抗体特异性。EP由VP0、VP1和VP3构成，而FP的VP0被剪切，故由VP1-VP4构成。EP和FP比例分别为41%和59%。CsCl密度分别为1.26 g/cm3和1.34 g/cm3，纯度分别为70.5%和96.3%。中和试验显示，兔抗全病毒抗体具有中和作用，而兔抗CV-A4VP1～VP4结构蛋白抗体不具有中和作用。免疫原性强弱为：FP>EP>VP1-VP4。本研究建立了CV-A4纯化病毒结构蛋白的分析方法，研究了重组病毒蛋白及2种病毒颗粒的免疫原性及免疫持久性。对包括CV-A4的手足口病多价疫苗的研发策略以及质量控制具重要意义。
Abstract：To study the biochemical characteristics and immunogenicity of enterovirus coxsackievirus A4(CVA4)which causes hand,foot,and mouth disease. We Used a bacterial system to express the full-length or truncated GST-tagged structural proteins to prepare rabbit anti-CV-A4 VP1-VP4 antibodies,and purified CVA4 virions to prepare CV-A4 virus antiserum. Western Blotting(WB)combined with sodium dodecyl sulfate–polyacrylamide gel electrophoresis were applied to analyze protein profiles,purity,polyprotein processing of the empty particles(EP)and full particles(FP)of CV-A4 purified by CsCl density gradient centrifugation. WB and indirect immunofluorescence demonstrated antibodies specificity. EP were composed of VP0,VP1 and VP3,whereas the precursor VP0 of FP was cleaved into VP2 and VP4,so it was composed of VP1-VP4.The ratio of EP and FP was 41% and 59%,the density was 1.26 g/cm3and 1.34 g/cm3,and the purity was 70.5%and 96.3%,respectively,for EP and FP. Neutralization assays showed that the rabbit anti-whole virus antibody had neutralizing activity,whereas rabbit anti-CV-A4 VP1-VP4 antibodies did not have neutralizing activity.The immunogenicity of the different forms of antigens was FP>EP>VP1-VP4. An analytical method for the purified structural proteins of CV-A4 was established,and the immunogenicity and persistence of recombinant viral proteins and viral particles were studied. Our data are very important for the quality control of multivalent vaccines for hand,foot,and mouth disease due to CV-A4 infection.
[1] Brown B A, Pallansch M A. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus[J/OL]. Virus Res,1995,39(2-3):195-205. DOI:10.1016/0168-1702(95)00087-9.
[2] Phan V T, Nguyen T T, David P, Khanh H T,Nguyen K T,Tang C T,Ooi M H,Mary J C,Peter C M. Epidemiologic and virologic investigation of hand,foot,and diseasemouth,southern Vietnam,2005[J/OL]. Emerg Infect Dis,2007,13(11):1733-1741.DOI:10.3201/eid1311.070632
[3] Yan J J,Su I J,Chen P F,Liu C C,Yu C K,Wang J R. Complete genome analysis of enterovirus 71 isolated from an outbreak in Taiwan and rapid identification of enterovirus 71 and coxsackievirus A16 by RT-PCR[J/OL]. J Med Virol,2001,65(2):331-339. DOI:10.1002/jmv.2038
[4] Chang L Y,Lin T Y,Huang Y C,Tsao K C,Shih S R,Kuo M L,Ning H C,Chung P W,Kang C M.Comparison of enterovirus 71 and coxsackie-virus A16clinical illnesses during the Taiwan enterovirus epidemic,1998[J/OL]. Pediatric Infect Dis J,1999,18(12):1092-1096. DOI:10.1097/00006454-199912000-00013
[5] Bible J M,Pantelidis P,Chan P K,William Tong C Y.Genetic evolution of enterovirus 71:epidemiological and pathological implications[J/OL]. Rev Med Virol,2007,17(6):371-379. DOI:10.1002/rmv.538.
[6] Podin Y,Gias E L,Ong F,Leong Y W,Yee S F,Yusof M A,Perera D,Teo B,Wee T Y,Yao S C,Yao S K,Kiyu A,Arif M T,Cardosa M J. Sentinel surveillance for human enterovirus 71 in Sarawak,Malaysia:lessons from the first 7 years[J/OL]. BMC Public Health,2006,7(6):180-181. DOI:10.1186/1471-2458-6-180
[7]杨祥，徐长征，陈金华，孟胜利，王泽鋆，申硕，陈晓琦.2019年EV-A71疫苗接种地区手足口病肠道病毒分子流行病学分析[J/OL].中国生物制品学杂志，2021,34(07):843-848. DOI:10.13200/j.cnki.cjb.003379
[8]徐长征，文丹宁，周金戈，罗剑锋，王泽鋆，申硕，李华东，陈晓琦. 2018年武汉地区手足口病肠道病毒分子流行病学分析[J/OL].中国生物制品学杂志，2020,33(11):1262-1269. DOI:10.13200/j.cnki.cjb.003196
[9] Meng X D,Tong Y Q,Wei Z N,Wang L,Mai J Y,Wu Y,Luo Z Y,Li S P,Li M,Wang S Q,Wei S,Gong W S,Zhang W S,Hu X Z,Huang J,Shi J,Yang G,Meng S L,Wang Z J,Guan X H,Shen S.Epidemical and etiological study on hand, foot and mouth disease following EVA71 vaccination in Xiangyang,China[J/OL]. Sci Rep,2020,10(1):20909. DOI:10.1038/s41598-020-77768-7
[10]张颖，甄若楠，谢华萍，陈纯，耿进妹，刘静雯，狄飚，王鸣. 2010-2015年广州地区手足口病Cox A6、Cox A4和Cox A10的病原监测和流行分析[J].疾病监测，2016,31(10):817-823.
[11]Lim H,Ju H I,Lee J A,Yoo J S,Lee S W,Chung G T,Choi YK,Chung J K,Cho S J,Lee J W. The immunogenicity and protection effect of an inactivated coxsackievirus A6,A10,and A16 vaccine against hand,foot,and mouth disease[J/OL]. Vaccine,2018,36(24):3445-3452. DOI:10.1016/j.vaccine.2018.05.005
[12]Hu Y F,Yang F,Du J,Dong J,Zhang T,Wu Z Q,Xue Y, Jin Q. Complete genome analysis of coxsackievirus A2,A5,and A10 strains isolated from hand, foot, and mouth disease patients in China revealing frequent recombination of human enterovirus A[J/OL]. J Clin Microbiol,2011,49(7):2426-2434.DOI:10.1128/JCM.00007-11
[13]Liu C C,Guo M S,Wu S R,Lin H Y,Yang Y T,Liu W C,Chow Y H,Shieh D B,Wang J R,Chong P.Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles[J/OL].Antiviral Res,2016,129:58-66. DOI:10.1016/j.antiviral.2016.02.008
[14]Cai Y,K Z,Liu Q,Leng Q,Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses[J/OL]. Vaccine,2014,32(21):2406-2412. DOI:10.1016/j.vaccine.2014.03.012
[15]Caine E A,Fuchs J,Das S C,Partidos C D,Osorio J E. Efficacy of a trivalent Hand,foot,and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16and A6 in Mice[J/OL]. Viruses,2015,7(11):5919-5932. DOI:10.3390/v7112916
[16]Li C,Wang J C,Taylor M W,Zlotnick A. In vitro assembly of an empty picornavirus capsid follows a dodecahedral path[J/OL]. J Virol,2012,86(23):13062-13069. DOI:10.1128/JVI.01033-12
[17]Bishop N E,Anderson DA. RNA-dependent cleavage of VP0 capsid protein in provirions of hepatitis A virus[J/OL]. Virology,1993,197(2):616-623. DOI:10.1006/viro.1993.1636
[18]Compton S R,Nelsen B,Kirkegaard K. Temperaturesensitive poliovirus mutant fails to cleave VP0 and accumulates provirions[J/OL]. J Virol,1990,64(9):4067-4075. DOI:10.1128/JVI.64.9.4067-4075.1990
[19]Tseng F C,Huang H C,Chi C Y,Lin T L,Liu C C,Jian J W,Hsu L C,Wu H S,Yang J Y,Chang Y W,Wang H C, Hsu Y W, Su I J, Wang J R.Epidemiological survey of enterovirus infections occurring in Taiwan between 2000 and 2005:analysis of sentinel physician surveillance data[J/OL]. Med Virol,2007,79:1850-1860. DOI:10.1002/jmv.21006
[20]姚学君，姜仁杰，管书慧，刘秀兰.中国大陆地区柯萨奇病毒A组4型VP1区基因特征分析[J].中国人兽共患病学报，2018,11:1021-1025.
[21]He Y Q,Chen L,Xu W B,Yang H,Wang H Z,Zong W P,Xian H X,Chen H L,Yao X J,Hu Z L,Luo M,Zhang H L,Ma H W,Cheng J Q,Feng Q J,Zhao D J.Emergence, circulation, andspatiotemporal phylogenetic analysis of coxsackievirus a6-and coxsackievirusa10hand-associated, foot, and mouth disease infections from 2008 to 2012 in Shenzhen,China[J/OL]. J Clin Microbiol,2013,51(11):3560-3566.DOI:10.1128/JCM.01231-13
[22]Yang Q,Ding J Y,Cao J H,Huang Q C,Hong C,Yang B. Epidemiological and etiological characteristics of hand,foot,and mouth disease in Wuhan,fromChina2012 to 2013:outbreaks of coxsackieviruses A10[J/OL]. J Med Virol,2015,87(6):954-960. DOI:10.1002/jmv.24151
[23]Hogle J M,Chow M,Filman D J. The structure of poliovirus[J/OL]. Science Am,1987,256(3):42-49.DOI:10.1038/scientificamerican0387-42
[24]Ehrenfeld E. Poliovirus:the molecular biology of poliovirus[J/OL],Science,1986,231(4738):627.DOI:10.1126/science.231.4738.627
[25]Cao J,Liu H,Qu M,Hou A,Zhou Y,Sun B,Cai L J,Gao W H,Jiang C L. Determination of the cleavage site of enterovirus 71 VP0 and the effect of this cleavage on viral infectivity and assembly[J/OL]. Microb Pathog, 2019, 134:103568. DOI:10.1016/j.micpath.2019.103568
[26]Adeyemi O O,Nicol C,Stonehouse N J,Rowlands D J. Increasing type 1 Poliovirus capsid stability by thermal selection[J/OL]. J Virol,2017,91(4):e01586-16.DOI:10.1128/JVI.01586-16
[27]Rombaut B,Jore J P. Immunogenic,non-infectious polio subviral particles synthesized in Saccharomyces cerevisiae[J/OL]. J Gene Virol,1997,78(8):1829-1832. DOI:10.1099/0022-1317-78-8-1829
[28]Jin W P,Lu J,Zhang X Y,Wu J,Wei Z N,Mai J Y,Qian S S,Yu Y T,Meng S L,Wang Z J,Shen S.Efficacy of coxsackievirus A5 vaccine candidates in an actively immunized mouse model[J/OL]. J Virol,2020,95(6):e01743-20. DOI:10.1128/JVI.01743-20
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004065
中图分类号:R373.23
引用信息:
[1]田宇璇,魏真妮,安欢欢,等.柯萨奇病毒A组4型生物化学特性及免疫原性分析[J].病毒学报,2022,38(03):581-590.DOI:10.13242/j.cnki.bingduxuebao.004065.
基金信息:
湖北省技术创新专项（重大专项）（项目号：2017ACA078）;题目：手足口病双价灭活疫苗的研制~~
2021-08-02
2021
2021-08-12
2021-11-19
2021
1
2021-11-22
2021-11-22
2021-11-22